BASF's Aggressive Growth Strategy

Paper Summary:

The paper explores BASF's aggressive growth strategy and reviews how their focus on non-cyclical operational aspects has helped boost company growth. The paper shows the truth in their popular slogan "We don't make a lot of the products you buy. We make a lot of the products you buy better".

Outline:
Unbridled Aggression
Cyclical Implications
Too Aggressive?

From the Paper:

"Since Sean Milmo's seven-year old Chemical Market Reporter article on BASF (which originally stood for Badische Anilin-und Soda-Fabrik), the record sales he discussed in "BASF outlines growth strategy in major markets" have been broken time and again. BASF remains strong in cyclical and commodity products and continues to increase earnings in non-cyclical operations as well. In fact, the third quarter of 2006 marked the thirteenth quarter in a row in which the company has posted sales growth. The chemical company has effectively resisted the urge to rest on its collective laurels, and has recently (2006) acquired Engelhard, Degussa Construction Chemicals and Johnson Polymer. Initially, Englehard's board of directors rejected BASF's bid ($37/share) stating they believed it to be "inadequate and opportunistic." Not to be denied, BASF increased their bid by $1/share, which Engelhard eventually accepted. This approach personifies the chemical giant's approach to growth: they are aggressive!"

Sample of Sources Used:

• "Agency Halts Sale of a Modified Rice," New York Times, March 2007
• Aki Tsukioka, "Takeda Pharmaceuticals Transfers All BASF Takeda Vitamin Shares to BASF Japan," JCNN News Summaries, January 2006, p. 1
• "BASF: Acquisitions strengthen profitable growth," M2 Presswire, November 2006, p. 1
• "BASF GROUP: BASF raises prices for formic acid and 2-ethylhexanoic acid," M2 Presswire, March 2007, p. 1
• "Five Vitamin Concerns Are Fined by Canada In Price-Fixing Case," Wall Street Journal, September 1999

More papers on BASF's Aggressive Growth Strategy:

• Research Paper # 96488 : "BASF Growth"
• Term Paper # 103878 : "Pfizer's Growth Strategy"

APA Citation:

MLA Citation: